These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1146463)

  • 1. [Preliminary results of immuno-surgical treatment of primary melanoma (author's transl)].
    Vanwicjk R; Rustin P; Malek-Mansour S; Castermans-Elias S; Castermans A
    Acta Chir Belg; 1975 Jul; 74(4):430-40. PubMed ID: 1146463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The nonspecific epifocal Malek-Mansour immunotherapy of malignant cutaneous melanoma using DNCB].
    Illig L; Paul E
    Hautarzt; 1976 Dec; 27(12):579-87. PubMed ID: 1010745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosurgical approach to the treatment of malignant melanoma using 2,4-dinitrochlorobenzene (DNCB).
    Lukács L; István M
    Neoplasma; 1984; 31(4):437-45. PubMed ID: 6472514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
    Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
    Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The characterization of tumour-associated membrane-bound antigens and their implementation in the treatment of malignant melanoma (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr Suppl; 1979; 97():3-32. PubMed ID: 106559
    [No Abstract]   [Full Text] [Related]  

  • 6. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
    Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Contribution to treatment of malignant melanoblastoma by the local application of DNCB (author's transl)].
    Duchková H; Richter J; Kubíková M
    Cesk Dermatol; 1978 Jun; 53(3):169-72. PubMed ID: 679282
    [No Abstract]   [Full Text] [Related]  

  • 8. [Specific immune reactivity in patients with malignant melanoma (author's transl)].
    Poljak-Blazi M; Montani D; Ferle-Vidović A; Boranić M
    Lijec Vjesn; 1977 Dec; 99(12):735-8. PubMed ID: 607047
    [No Abstract]   [Full Text] [Related]  

  • 9. [Surgical management of orbital malignant melanoma: our experience and a report of three cases].
    Poli T; Mora P; Reichegger V; Ricci R; Corradi D; Gandolfi SA; Sesenna E
    Klin Monbl Augenheilkd; 2007 Oct; 224(10):794-8. PubMed ID: 17952825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adjuvant DNCB immunotherapy in malignant melanoma].
    Weidner F; Djawari D
    Z Hautkr; 1979 May; 54(10):436-43. PubMed ID: 473840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation and arming of lymphocyte mediated immunity by sera from melanoma patients.
    Vanwijck R; Bouillenne C; Malek-Mansour S
    Eur J Cancer (1965); 1975 Apr; 11(4):267-76. PubMed ID: 1079770
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical trial of local immunomodulation with DNCB in cases of advanced melanoma of the skin].
    Budzanowska E; Pawlicki M
    Przegl Dermatol; 1988; 75(1):29-34. PubMed ID: 3290999
    [No Abstract]   [Full Text] [Related]  

  • 13. Epifocal dinitrochlorobenzene therapy in malignant melanoma (experience during the last eight years).
    Illig L; Paul E; Bödeker RH
    Anticancer Res; 1984; 4(4-5):293-8. PubMed ID: 6486734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of dermatologists', surgeons' and general practitioners' surgical management of cutaneous melanoma.
    McKenna DB; Marioni JC; Lee RJ; Prescott RJ; Doherty VR
    Br J Dermatol; 2004 Sep; 151(3):636-44. PubMed ID: 15377351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
    Hsueh EC; Famatiga E; Shu S; Ye X; Morton DL
    Ann Surg Oncol; 2004 Oct; 11(10):892-9. PubMed ID: 15383418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Decrease in immunoreactivity in melanoma. Analysis of DNCB tests in the literature].
    Remy W; Dorn R; Ulm K; Mayerhausen W
    Z Hautkr; 1986 Dec; 61(24):1767-77. PubMed ID: 3825218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma of the ear: prognostic factors and surgical strategies.
    Jahn V; Breuninger H; Garbe C; Moehrle M
    Br J Dermatol; 2006 Feb; 154(2):310-8. PubMed ID: 16433802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Primary free dermatoplasty in surgical treatment of skin melanoma].
    Zhukov VM
    Vopr Onkol; 1977; 23(4):3-9. PubMed ID: 329578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Secretion of immunoglobulins in malignant melanoma of the skin].
    Babakova SV; Kuznetsov VA; Gorodilova VV; Konradov AA; Chervonnaia LV
    Vopr Onkol; 1988; 34(3):314-8. PubMed ID: 3358294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cutaneous malignant melanomas. A study of 13 cases observed in a general surgery department (author's transl)].
    Yangni-Angate A; Khoury J; Kanga M; Zeze B; Turquin H; Guhl G; Echimane A; Merrien Y
    Med Trop (Mars); 1982; 42(1):83-7. PubMed ID: 7078382
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.